This report is part of the Hemingway Innovation Atlas Series, an independent assessment of the evidence, maturity and adoption of mental health innovations. Each report aims to create greater transparency on the state of an innovation and to make recommendations on where efforts would move the innovation forward and provide better outcomes for patients.
This report focuses on ketamine as a treatment for treatment-resistant depression.
Hemingway Innovation Atlas, Ketamine: Executive Summary
Executive summary with the key findings and recommendations.
Hemingway Innovation Atlas, Ketamine: Full Report
Full report with the evidence review, data and references.
Key Summary & Findings
Ketamine changed what seemed possible in depression treatment. It was already an established generic anaesthetic when a small trial in 2000 showed that it could produce antidepressant effects within hours [1]. Then, in 2006, another trial showed it could do the same in people with treatment-resistant depression (TRD) [2]. Ketamine offered something unprecedented in antidepressant drug development: the prospect of relieving depression within hours, rather than weeks. It acts on the brain's glutamate system, a different system from most antidepressants.
Today, ketamine reaches patients in three main forms: esketamine, generic intravenous (IV) ketamine and at-home ketamine.
Esketamine is a nasal spray sold as Spravato, developed from one of the two molecular forms of ketamine by Janssen, part of Johnson & Johnson. It is the only ketamine product with a marketing authorisation for depression [3], supported by a commercial programme of clinical trials and regulatory approvals. Worldwide sales reached $1.7 billion in 2025, mostly in the US [4, 5]. Major US commercial insurers cover it, while publicly funded health systems have reached different decisions: it is funded for eligible patients in Australia and Germany and accepted for use in Scotland, but not recommended by the National Institute for Health and Care Excellence (NICE) in England and Wales [6–10].
Generic IV ketamine is the established anaesthetic given by infusion and used off-label to treat depression, usually in specialist clinics. Research has shown rapid antidepressant effects, but its development has been led largely by academic researchers rather than a commercial sponsor, leaving gaps in evidence on longer-term use. As a generic, it has no sponsor with an incentive to fill them. The drug itself is inexpensive: at Oxford, a dose costs around £1, although each supervised infusion is charged at £265 [11, 12]. Norway has funded it nationally in specialist care since 2025 while collecting further evidence. Elsewhere, access is mainly through self-pay clinics or locally commissioned services [13, 14].
At-home ketamine involves patients taking ketamine outside a clinic, often supplied by US telehealth providers as compounded medicines. Providers use different formulations, doses and levels of supervision, offering an alternative to repeated clinic visits. The market has expanded without the regulatory trials required of an approved depression medicine [15]: the largest published studies are based on providers' own patient records and have no control groups [16, 17]. The US Food and Drug Administration (FDA) has warned about the risks of compounded ketamine taken without a clinician present [18], while products specifically developed for home use are undergoing clinical testing.
While ketamine can lift depression within hours for some people whose other treatments have failed, it has limitations. Not everyone responds, and the benefit often fades, so treatment may need to be repeated. In clinics, each dose is given under supervision because of short-term side effects and the risk of misuse.
Patients would like to know if ketamine will work for them, how long the benefit will last, how long treatment needs to be continued, and whether improvement means recovery.
Providers have to staff and equip repeated treatment without a reliable way to know who will benefit.
Health systems must decide which form of ketamine, if any, to fund, for which patients and instead of what. They must do this with few head-to-head trials and little evidence on when treatment can be stopped.
This is also an equity question. Who gets ketamine depends on whether they can pay and where they live. In one US study, patients living 50 miles or more from an esketamine treatment centre had a 92.8% lower rate of starting treatment than those living within nine miles [19].
Some innovators are trying to address these challenges, aiming to make treatment easier to deliver or longer-lasting. The furthest advanced product for use at home, R-107, an extended-release tablet, is starting Phase 3, according to its developer, Tasman Therapeutics, which expects results in 2027 [20]. Freedom Biosciences is combining ketamine with a second drug to extend its effect, and has FDA clearance for an early trial [21]. Each still has to show it is easier to deliver or longer-lasting without losing benefit or safety. Others are working on predicting who will respond, including a Wellcome-funded European database for biomarker research [22], but there is still no validated way to do so [23, 24].
However, individual innovators cannot address some of the adoption challenges. Health systems set out the questions their funding decisions depend on separately, one product and one country at a time, often after the trials have been designed. So developers have no shared statement, across treatments, of what health systems will need, and the same trial can satisfy one system and not another.
The Hemingway View
Ketamine has changed what is possible in treating depression, but its place in care is still being worked out. For people with treatment-resistant depression (TRD), who have often tried several treatments without enough relief, its rapid effects can be profound. Some experience a substantial improvement within hours, after other treatments have failed. That improvement may not last, and many patients do not respond, but for those who do, it can offer relief that had seemed out of reach.
The opportunity is to make ketamine's benefits last longer, reach more people and lead to more meaningful recovery. We see the most important areas of innovation in work that helps identify who is most likely to respond, reduces the need for repeated treatment and establishes when treatment can safely stop. Longer-lasting formulations could also ease the burden of clinic visits. Better evidence on maintenance treatment, psychological support and longer-term outcomes could help clinicians use ketamine more effectively. We do not expect a step-change in how well ketamine works. The gains are more likely to come from these incremental improvements, and from better decisions about who gets it, where and at what cost.
The greatest obstacle to progress is the gap between the evidence being produced and the decisions health systems need to make. Esketamine has a substantial regulatory evidence base, yet health systems disagree on whether its benefits justify its costs. Generic IV ketamine is inexpensive and has evidence of rapid antidepressant effects, but no commercial sponsor has an incentive to fund the larger, longer-term and comparative studies needed for health technology assessment (HTA) bodies to make informed decisions on its use. Meanwhile, some services collect information that could help resolve these questions, but each in its own way, so the results cannot yet be read together. New evidence and new decisions are due in the next few years, which gives health systems an opportunity to set out now what they need to know: head-to-head trials of IV ketamine and esketamine are due to complete between 2027 and 2030, NRx is aiming for FDA approval in 2027, and Norway’s reassessment is due by the end of 2028.
We think the field should start with the decisions that need to be made about ketamine, and work backwards to the evidence required. We propose three steps:
Agree what health systems need to know. Bring together HTA bodies, US payers, health services and patients to identify the uncertainties that matter most for funding decisions. Start with generic IV ketamine, drawing on the questions already raised in assessments of esketamine and of IV ketamine. Patients should help define what counts as meaningful benefit, beyond symptom scores, and which side effects and demands of treatment are acceptable.
Establish what the evidence can already answer. Map existing studies, routine-care data and forthcoming research against those questions, including when results will be available and when health systems are due to review their decisions. Work with the clinicians and providers who hold the data. For generic IV ketamine, which has no sponsor to take results to health systems, the map would show when an assessment or reassessment would be worthwhile.
Fill the gaps that could change decisions. Identify which questions developers can answer in trials, which require longer-term follow-up in routine care, and which have no clear owner. Agree when a health system could fund treatment while collecting further evidence. Commission new research where it could change a funding or clinical decision, rather than adding studies that leave the central uncertainties unresolved.
This would give developers, researchers and funders a shared set of evidence priorities to inform their programmes from the start. It would also allow research and treatment to progress together. Services could follow patients over time to understand who benefits, how long improvements last, when treatment stops and what happens afterwards. Research clinics could test possible predictors of response in patients who reflect those seen in practice. Norway has already shown that a health system can fund IV ketamine while requiring further evidence. Its reassessment, due by the end of 2028, offers a useful point against which to measure progress.
There are also safeguards that should not depend on who pays. Unless a product is authorised for depression on other terms, ketamine treatment for depression should be started by a psychiatrist, with monitoring after each dose given in a clinic and a clear plan for any treatment taken at home. Outcomes should be recorded, with clear rules for continuing and stopping. These conditions matter for privately funded treatment as well as publicly funded services.
Taking this forward would require an independent convenor, trusted by health systems and not tied to any ketamine product. It could work through existing HTA collaborations, with public and philanthropic support for convening, mapping and research that addresses the most important gaps. A first statement of shared evidence priorities, alongside a map of existing and forthcoming studies, could be produced within a year.
After publication, we will discuss this proposal with HTA bodies, payers, health services, funders and patient groups, to test it and to find who could take it forward.
Ketamine is an opportunity to improve depression care, but also to improve how promising treatments are evaluated and adopted. If health systems and researchers can establish what evidence is needed for a cheap drug with a substantial evidence base that already helps some patients, they can build a better route for the treatments that follow, including psychedelics such as psilocybin.
PRO
Hemingway Community Research Briefing
Join the authors of this report, Anna Zecharia and Steve Duke for a live discussion on the findings and an open Q&A about the future of ketamine.
Date: 24 November, 4pm GMT
Hemingway Innovation Atlas, Ketamine: Social Media Assets
Download images of the report to share on social.
About this report
Hemingway is an organisation focused on advancing mental health innovation to improve population mental health. The Hemingway Innovation Atlas analyses emerging approaches for treating mental disorders through a systems lens. Its goal is to create greater transparency on the state of an innovation and to make recommendations on where efforts would move the innovation forward and provide better outcomes for patients.
While researchers, clinicians, developers, investors, regulators and health systems each see part of an innovation’s picture, they often work from different evidence and incentives. The Atlas looks at the whole system, across countries and across very different kinds of innovation, from medicines to devices and digital tools. It uses a single framework, which lets very different fields be compared. Each briefing applies this framework to one innovation, assessing where it stands and what is holding it back.
Credits & Disclosures
Authors
Designers
Published
Last Updated
Anna Zecharia, PhD & Steve Duke
Elizabeth Hong & Hugo Welke
18th November 2026
18th November 2026
About the authors
Anna Zecharia, PhD
Anna Zecharia leads Hemingway’s Innovation Atlas. She is an independent adviser and consultant in research, innovation and policy, with a focus on mental health, and Vice Chair of the Mental Health Foundation’s Board of Trustees. She was previously Director of Programmes & Partnerships and Deputy Executive Director at the International Alliance of Mental Health Research Funders and, before that, Director of Policy & Public Affairs at the British Pharmacological Society. Anna began her career as a research scientist, with a PhD in neuropharmacology from Imperial College London.
Steve Duke
Steve Duke is the Founder and CEO of Hemingway. He is the Editor of The Hemingway Report, an industry publication on mental health innovation and the host of the Hemingway Community, a global network for mental health innovators. Before Hemingway, Steve worked at McKinsey & Company as a management consultant and as an executive at a fintech and a healthtech company. He holds a Bachelor of Engineering from University College Dublin and University of New South Wales.
Disclosures
The series is produced by Hemingway in partnership with the One Mind Accelerator. It is partially funded by Wellcome through a grant that supports Hemingway’s overarching work on coordination and knowledge creation for mental health innovation. The One Mind Accelerator team contributed perspectives and made introductions to support the briefing’s development. Two companies discussed in this briefing, Freedom Biosciences and Heading Health, are in the One Mind Accelerator portfolio. Hemingway has no stake in any product discussed. The analysis and conclusions are Hemingway’s own.
Corrections
For any corrections or feedback, please send an email to [email protected]
This briefing is for information only. It is not medical advice and does not recommend any treatment for any individual. Anyone considering ketamine treatment should speak to a doctor. If you are struggling or having thoughts of suicide, support is available. In the UK and Ireland, you can call Samaritans free on 116 123. In the US, call or text 988. Elsewhere, contact your local emergency services.
References:
Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 2000;47(4):351-354. doi:10.1016/S0006-3223(99)00230-9
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006;63(8):856-864. doi:10.1001/archpsyc.63.8.856
European Medicines Agency. Spravato: EPAR – product information. Accessed 12 October 2026. https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf
Johnson & Johnson. Johnson & Johnson reports Q3 2026 results, raises 2026 guidance (sales schedules: SPRAVATO). Business Wire. 13 October 2026. Accessed 13 October 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance
Johnson & Johnson. Johnson & Johnson reports Q4 and full-year 2025 results. 21 January 2026. Accessed 12 October 2026. https://s203.q4cdn.com/636242992/files/doc_news/Johnson--Johnson-reports-Q4-and-Full-Year-2025-results-2026.pdf
Overview | Esketamine nasal spray for treatment-resistant depression | Guidance | NICE. 14 December 2022. Accessed 2 September 2026. https://www.nice.org.uk/guidance/ta854
esketamine (Spravato). Scottish Medicines Consortium. Accessed 2 September 2026. https://scottishmedicines.org.uk/medicines-advice/esketamine-spravato-full-smc2258/ (Detailed advice: https://scottishmedicines.org.uk/media/5353/esketamine-spravato-final-august-2020docx-for-website.pdf)
Australian Government Department of Health and Aged Care. PBS medicine status: esketamine. Accessed 2 September 2026. https://www.pbs.gov.au/medicinestatus/document/1347
Alvear M. Coverage Policies for Ketamine-Based Depression Therapies Among Major U.S. Commercial Insurers: Cross-Sectional Analysis of 18 Insurers Covering 85.9 Million Members (August 2025). Zenodo. Preprint posted online 13 September 2025. doi:10.5281/ZENODO.17113526
Gemeinsamer Bundesausschuss. Esketamin bei schwerer therapieresistenter Depression: G-BA sieht Anhaltspunkt für beträchtlichen Zusatznutzen. 21 September 2023. Accessed 8 October 2026. https://www.g-ba.de/service/fachnews/84/ (Decision and Tragende Gründe, 21 September 2023: https://www.g-ba.de/downloads/39-261-6170/2023-09-21_AM-RL-XII_Esketamin_D-930.pdf)
Oxford Health NHS Foundation Trust. Pricing. Interventional Psychiatry Service. Last reviewed 10 March 2026. Accessed 28 October 2026. https://oxfordhealth.nhs.uk/ips/pricing/
Oxford Health NHS Foundation Trust. FAQ. Ketamine for treatment-resistant depression, Interventional Psychiatry Service. Last reviewed 29 April 2026. Accessed 28 October 2026. https://oxfordhealth.nhs.uk/ips/ketamine-trd/faq/
Ohm IK, Flatby AV, Stoinska-Schneider A, Hafstad E. Intravenous ketamine for treatment-resistant depression: a health technology assessment. Oslo: Norwegian Medical Products Agency; 2025 (report ID2022_018, dated 13 June 2025). Accessed 8 October 2026. https://www.dmp.no/contentassets/68facb7a6e27464f9140174cb55503e1/id2022-018_intravenous-ketamine-for-trd_offentlig.pdf
Ketamin. Nye metoder. Accessed 14 September 2026. https://www.nyemetoder.no/metoder/ketamin/
US Food and Drug Administration. Compounding laws and policies. Accessed 12 October 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
Parks AC, Woodward AL, Henry RD et al. At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study. Journal of Medical Internet Research. 2026;28:e92647. doi:10.2196/92647
Mathai DS, Hull TD, Vando L et al. At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data. Journal of Affective Disorders. 2024;361:198-208. doi:10.1016/j.jad.2024.05.131
US Food and Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. 10 October 2023. Accessed 12 October 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine
Joshi K, Liberman JN, Parab P et al. Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 2024;85(2). doi:10.4088/JCP.23m15102
Tasman Therapeutics Announces Strategic Partnership with Osmind to Advance R-107 for Depressive Disorders. Tasman Therapeutics. 12 August 2026. Accessed 13 October 2026. https://www.tasmantherapeutics.com/insights/tasman-therapeutics-announces-strategic-partnership-with-osmind-to-advance-r-107-for-depressive-disorders
Freedom Biosciences. Freedom Biosciences announces FDA approval of IND application for FREE001 in patients with treatment-resistant depression. PR Newswire. 25 April 2024. Accessed 12 October 2026. https://www.prnewswire.com/news-releases/freedom-biosciences-announces-fda-approval-of-ind-application-for-free001-in-patients-with-treatment-resistant-depression-302126653.html
Where are the biomarkers in psychiatry? ECNP. 16 January 2026. Accessed 13 October 2026. https://www.ecnp.eu/news/press-office/where-are-the-biomarkers-in-psychiatry/
DeepPsy | More clarity in depression treatment decisions. https://deeppsy.io/en/ Accessed 13 October 2026.
Provaznikova B, De Bardeci M, Altamiranda E et al. Predictive value of EEG/ECG Biomarkers for Treatment Response in Depression. medRxiv (preprint). 2026. doi:10.64898/2026.03.25.26349315


